What Is Cogent Biosciences, Inc. (COGT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Cogent Biosciences, Inc. at its current price of $39.30. The composite intrinsic value is estimated at $22.15 (-43.6% average return), with 7 models flagging overvaluation risk. Notably, Sentiment SOTP sees the most upside at +29.3% (fair value: $50.80), while ML-RIV is the most conservative at -99.6% ($0.15). The spread between these extremes — +128.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About COGT?
10 of 13 models are currently active for COGT. Of these, 3 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates COGT's intrinsic value at $16.63, implying -57.7% downside from the current price. See which stocks rank higher →
How Does COGT Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, COGT ranks #248 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Cogent Biosciences, Inc. competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is COGT a Value Trap?
CirclFi's Value Trap algorithm assigns COGT a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Cogent Biosciences, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Cogent Biosciences, Inc. is rated at 4.7/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +128.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every COGT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across COGT's 10 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad